Detailed Narrative
Strong Q2 FY25 Performance Driven by Packaging Films and Aseptic Business
Uflex reported a consolidated top line of INR 3,853 crores in Q2 FY25, marking a 13.7% year-on-year increase, continuing the positive momentum from Q1. This growth was primarily fueled by the Packaging Films business, which saw a 23.4% rise in revenue and a 14.6% increase in sales volume. The Aseptic Packaging business also demonstrated robust performance, achieving a 93% capacity utilization in Q2 FY25, up from 83% in the previous year, and recording a 17.6% year-on-year sales volume growth. Normalized EBITDA for the quarter stood at INR 438 crores, an increase from INR 408 crores in Q2 FY24.
Improved Margins in Packaging Films, Mixed Outlook for H2
The BOPET industry experienced a significant gross margin increase of approximately 200% in Q2 FY25 over Q1, with a further 20% increase in the current quarter. Management expressed confidence that BOPET margins would remain at reasonable levels in H2 FY25, with potential for further improvement. In contrast, the BOPP industry saw a 36% gross margin increase in Q2 over Q1 but has since corrected to Q1 levels in the current quarter. The company hopes for a return to Q2 levels for BOPP margins in the second half of the fiscal year.
Aseptic Packaging Capacity Expansion and Global Strategy
Uflex is actively expanding its Aseptic Packaging capacity to 12 billion packs by the end of December 2024, anticipating an 83% utilization rate in Q4 FY25 and a 20% year-on-year sales volume increase. A new greenfield Aseptic Packaging facility in Egypt is planned, projected to deliver 20% higher EBITDA at full utilization. This strategic move aims to capitalize on Egypt's local market demand of 5 billion packs annually and its advantageous position for exports to Europe and Africa, replicating India's success.
Impact of Currency Devaluation and High Finance Costs
The company continues to face significant currency translation losses from Nigeria, Mexico, and Egypt, totaling INR 92-93 crores in Q2 FY25, an improvement from INR 180 crores in Q1. While management categorizes these as 'notional losses,' they impact reported profits. Gross and net debt stood at INR 5,800 crores as of September 30, 2024, with annual finance costs projected around INR 700 crores. Attempts to raise funds via QIP were put on hold due to unfavorable market conditions, contributing to investor concerns about profit erosion.
Strategic Capex and Debt Management
Uflex incurred INR 629 crores in total capex in H1 FY25, with key projects including a PET chips plant in Egypt and a CPP facility in Mexico. The Egypt PET chips plant, expected to complete in H2 FY25 (Jan-March), is projected to boost overall EBITDA by approximately 5% at full capacity. The company forecasts an annual capex of INR 1,000 crores for the current year and around USD 80 million for the next fiscal year, with maintenance capex estimated at INR 200-250 crores annually. Normal debt amortization is expected to be around INR 1,000 crores annually, with INR 1,000 crores to be repaid this year at an average cost of borrowing around 10%.
Recycling Business Outlook and Regulatory Environment
Uflex maintains optimism for its recycling business, having established plants in India and overseas. However, the immediate momentum is constrained by delays in the implementation of EPR (Extended Producer Responsibility) guidelines in Europe and India. Management noted that while Uflex is prepared for these regulations, industry-wide readiness and government postponements are slowing the adoption and impact of this business segment, which is dependent on regulatory enforcement.